PharmaCyte Biotech Officers to Attend 2015 BIO International Convention
10 June 2015 - 11:25PM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today announced that its Chief
Executive Officer, Kenneth L. Waggoner, JD, and its Chief Operating
Officer, Gerald W. Crabtree, Ph.D., will attend the 2015 BIO
International Convention to be held June 16-18, 2015, at the
Philadelphia Convention Center in Philadelphia, Pennsylvania.
This year’s BIO International Convention is
termed “The Global Event for Biotechnology.” This Convention is the
world’s largest biotechnology gathering. Attendees at the
Convention will have the opportunity to reach influential decision
makers and high-level executives who come to BIO to discover new
“players” in the biotechnology sector, evaluate emerging
technologies and even form new partnerships. The 2015 BIO
Convention will feature more than 1,700 exhibitors who will occupy
approximately 160,000 square feet of floor space. The exhibitors
will include: the top 25 pharmaceutical companies, the world’s
leading biotech companies, the top 20 Contract Research
Organizations and Contract Medical Organizations and more than 300
academic institutions. Major research laboratories, leading
consultants, service companies and government agencies will also be
represented.
Kenneth L. Waggoner, PharmaCyte Biotech’s Chief
Executive Officer, stated, “Attendance at the annual BIO
International Convention is really mandatory for a company like
ours which is relatively new to the biotechnology arena. This
year’s convention will present Dr. Crabtree and me with
opportunities to interact with diverse entities from around the
world at this single site in Philadelphia. Because of the proximity
of so many outstanding companies, organizations and institutions,
PharmaCyte Biotech will have the opportunity to develop new
relationships and foster already budding ones more easily and
quickly than might otherwise be possible.”
About PharmaCyte BiotechPharmaCyte Biotech is a
clinical stage biotechnology company focused on developing and
preparing to commercialize treatments for cancer and diabetes based
upon a proprietary cellulose-based live cell encapsulation
technology known as Cell-in-a-Box®. This unique and patented
technology will be used as a platform upon which treatments for
several types of cancer, including advanced, inoperable pancreatic
cancer, and diabetes are being built. PharmaCyte Biotech's
treatment for pancreatic cancer involves low doses of the
well-known anticancer prodrug ifosfamide, together with
encapsulated live cells, which convert ifosfamide into its active
or "cancer-killing" form. These capsules are placed as close to the
tumor as possible to enable the delivery of the highest levels of
the cancer-killing drug at the source of the cancer. This "targeted
chemotherapy" has proven remarkably effective in past clinical
trials. In addition, PharmaCyte Biotech is working towards
improving the quality of life for patients with advanced pancreatic
cancer and on treatments for other types of solid cancerous
tumors.
PharmaCyte Biotech is also developing treatments
for cancer based upon chemical constituents of the Cannabis plant,
known as cannabinoids. In doing so, PharmaCyte Biotech is examining
ways to exploit the benefits of Cell-in-a-Box® technology in
optimizing the anticancer effectiveness of cannabinoids, while
minimizing or outright eliminating the debilitating side effects
usually associated with cancer treatments. This provides PharmaCyte
Biotech the rare opportunity to develop “green” approaches to
fighting deadly diseases, such as cancer of the pancreas, brain and
breast, which affect hundreds of thousands of individuals worldwide
every year.
Safe HarborThis press release may contain
forward-looking statements regarding PharmaCyte Biotech and its
future events and results that involve inherent risks and
uncertainties. The words "anticipate," "believe," "estimate,"
"expect," "intend," "plan" and similar expressions, as they relate
to PharmaCyte Biotech or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte Biotech, could cause actual
results to differ materially from those set forth in the
forward-looking statements. They include PharmaCyte's ability to
continue as a going concern, delays or unsuccessful results in
preclinical and clinical trials, flaws or defects regarding its
product candidates, changes in relevant legislation or regulatory
requirements, uncertainty of protection of PharmaCyte Biotech’s
intellectual property and PharmaCyte Biotech’s continued ability to
raise capital. PharmaCyte Biotech does not assume any obligation to
update any of these forward-looking statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com